University of Miami’s Gift of Its 1994 Ibogaine IND to HHS Advances Open Science While Highlighting Modern Safety and Sourcing Needs

The University of Miami has gifted its 1994 ibogaine Investigational New Drug application to the federal government, making a historic regulatory file available as a public resource and setting an example for open science. MAPS, which provided early funding for the Miami program, welcomes the contribution while stressing that the filing reflects knowledge from 1994 and cannot replace current safety, pharmacokinetic, cardiac-risk, screening, monitoring, sourcing, and treatment data. MAPS says ibogaine research should proceed through ethical, rigorous and transparent review, with informed consent, provider training, equitable access, and clinical capacity sufficient to manage documented cardiac risks. The organization also emphasizes that iboga is a limited, slow-growing resource connected to communities, traditions, and land in Gabon, so US demand carries obligations beyond regulatory approval. The announcement urges researchers, clinicians, and regulators to collaborate and use MAPS’ updated Investigator’s Brochure.